New radioactive compound shows promise in targeting Hard-to-Treat cancers
NCT ID NCT07587996
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new radioactive drug called 177Lu-CTR-FAPI in 12 people with advanced solid tumors (breast cancer, sarcoma, or thyroid cancer) that had spread and no longer responded to standard treatments. The main goals were to see if the drug is safe and how it spreads in the body. The drug targets a protein called FAP, which is found in high amounts on these tumors, aiming to deliver radiation directly to cancer cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Hospital & Clinical Medical School, Lanzhou University
Lanzhou, Gansu, 730000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new protein drug shield kids with cancer from dangerous infections?
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A dab of gel on the breathing tube might spare surgery patients a sore throat — a trial puts it to the test.
- Can a deeper nerve block ease pain after breast surgery?
- Does breast cancer radiation harm a key immune gland? a study investigates
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?